We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.43%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$956M
AUM Growth
+$110M
Cap. Flow
+$88M
Cap. Flow %
9.21%
Top 10 Hldgs %
34.18%
Holding
136
New
4
Increased
63
Reduced
26
Closed
5

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$10.5M
2
ALGN icon
Align Technology
ALGN
+$9.68M
3
CELG
Celgene Corp
CELG
+$9.59M
4
ELV icon
Elevance Health
ELV
+$9.1M
5
COR icon
Cencora
COR
+$7.21M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$7.35M
2
CI icon
Cigna
CI
+$4.96M
3
BCR
CR Bard Inc.
BCR
+$4.65M
4
CNC icon
Centene
CNC
+$4.38M
5
ALKS icon
Alkermes
ALKS
+$4.36M

Sector Composition

Rank Sector Weight
1 Healthcare 94.19%
2 Financials 0.94%
3 Industrials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTRS icon
51
Viatris
VTRS
$20.1B
$5.68M 0.59%
181,200
-82,000
-31% -$2.78M
CERN
52
DELISTED
Cerner Corp
CERN
$5.31M 0.56%
74,500
– –
GNMK
53
DELISTED
GenMark Diagnostics, Inc
GNMK
$5.04M 0.53%
523,677
+118,499
+29% +$1.23M
TMO icon
54
Thermo Fisher Scientific
TMO
$198B
$4.88M 0.51%
25,808
+11,208
+77% +$2.03M
EGRX
55
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$4.86M 0.51%
81,550
-50,440
-38% -$3.05M
BMRN icon
56
BioMarin Pharmaceuticals
BMRN
$11.5B
$4.54M 0.48%
48,800
-16,200
-25% -$1.43M
ACAD icon
57
Acadia Pharmaceuticals
ACAD
$4.38B
$4.41M 0.46%
117,000
-69,000
-37% -$2.24M
AGN
58
DELISTED
Allergan plc
AGN
$4.2M 0.44%
20,500
-8,500
-29% -$1.98M
JNJ icon
59
Johnson & Johnson
JNJ
$609B
$4.09M 0.43%
31,500
– –
PRGO icon
60
Perrigo
PRGO
$1.48B
$3.93M 0.41%
46,468
-50,000
-52% -$3.89M
RMD icon
61
ResMed
RMD
$28.9B
$3.62M 0.38%
47,000
+10,900
+30% +$834K
BLUE
62
DELISTED
bluebird bio
BLUE
$3.45M 0.36%
1,938
+232
+14% +$324K
NBIX icon
63
Neurocrine Biosciences
NBIX
$17.2B
$3.43M 0.36%
56,000
+9,000
+19% +$475K
XRAY icon
64
Dentsply Sirona
XRAY
$2.81B
$3.26M 0.34%
54,500
+4,000
+8% +$238K
ESRX
65
DELISTED
Express Scripts Holding Company
ESRX
$3.13M 0.33%
49,500
– –
HSIC icon
66
Henry Schein
HSIC
$10B
$3.12M 0.33%
+48,450
New +$3.31M
AGIO icon
67
Agios Pharmaceuticals
AGIO
$2.36B
$3M 0.31%
45,000
– –
IBB icon
68
iShares Biotechnology ETF
IBB
$9.23B
$3M 0.31%
27,000
+6,000
+29% +$641K
MOH icon
69
Molina Healthcare
MOH
$11.7B
$2.99M 0.31%
43,500
+27,000
+164% +$1.76M
NKTR icon
70
Nektar Therapeutics
NKTR
$2.31B
$2.95M 0.31%
8,200
+5,333
+186% +$1.67M
ALKS icon
71
Alkermes
ALKS
$8.79B
$2.85M 0.3%
56,100
-81,500
-59% -$4.36M
MCK icon
72
McKesson
MCK
$98.5B
$2.77M 0.29%
18,000
– –
NUVA
73
DELISTED
NuVasive, Inc.
NUVA
$2.56M 0.27%
46,204
+10,900
+31% +$721K
UTHR icon
74
United Therapeutics
UTHR
$22.7B
$2.53M 0.26%
21,600
+13,800
+177% +$1.76M
TFX icon
75
Teleflex
TFX
$5.96B
$2.47M 0.26%
10,200
+3,200
+46% +$696K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2017 Portfolio in Review

As of Q3 2017, Bellevue Group held 136 positions worth $956M, up 13% from $846M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Bellevue Group deployed $88M of net new capital in Q3 2017, opening 4 new positions and adding to 63 existing holdings. Its largest new stake was Henry Schein: 48,450 shares worth $3.12M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Medtronic, an estimated $7.35M trimmed.

  • Bellevue Group's largest Q3 2017 buy was Henry Schein: 48,450 shares worth $3.12M.
  • Bellevue Group added most to Illumina in Q3 2017, an estimated $10.5M increase.
  • Bellevue Group's biggest Q3 2017 reduction was Medtronic, cutting an estimated $7.35M.
  • Bellevue Group fully exited China Biologic Products Holdings, Inc. in Q3 2017, selling an estimated $4.1M.
  • Bellevue Group's ten largest holdings make up 34% of its $956M portfolio in Q3 2017.
  • Bellevue Group opened 4 new positions and closed 5 in Q3 2017.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $956M.

Based on Bellevue Group's 13F filing for Q3 2017, filed 13 Nov 2017.